{
    "Clinical Trial ID": "NCT02761642",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Epoetin Beta",
        "  Anemic breast cancer participants received epoetin beta (NeoRecormon\u00ae) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week for a total of 12 weeks. Adjustments in the dose were implemented based on the participant's blood hemoglobin levels."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Adult female participants with histological diagnosis of breast cancer",
        "  Any type of chemotherapy planned for greater than or equal to (>/=) 9 weeks",
        "  Hemoglobin level less than (<) 11 grams per deciliter (g/dL)",
        "  Participants able to receive iron supplement, if necessary",
        "Exclusion Criteria:",
        "  Known or suspected contraindications to epoetin beta",
        "  Pregnancy or lactation period",
        "  Diagnosis of anemia only due to iron-deficiency",
        "  Diagnosis of thalasemic syndromes",
        "  Epilepsy and/or cerebral metastasis",
        "  Blood transfusion or treatment with any erythropoietic factor within 4 weeks before study start"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Response to Treatment Based on Hemoglobin Levels",
        "  Response was defined as increase of hemoglobin levels by at least 2 grams per deciliter (g/dL) as compared to baseline or the achievement of hemoglobin level of 12 g/dL after 12 weeks of treatment in the absence of red blood cells transfusion.",
        "  Time frame: Week 12",
        "Results 1: ",
        "  Arm/Group Title: Epoetin Beta",
        "  Arm/Group Description: Anemic breast cancer participants received epoetin beta (NeoRecormon  ) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week for a total of 12 weeks. Adjustments in the dose were implemented based on the participant's blood hemoglobin levels.",
        "  Overall Number of Participants Analyzed: 197",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  46.2        (38.2 to 54.3)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 17/197 (8.63%)",
        "  Neutropenia * 1/197 (0.51%)",
        "  Pancytopenia * 1/197 (0.51%)",
        "  Disease progression * 2/197 (1.02%)",
        "  Fatigue * 1/197 (0.51%)",
        "  General physical health deterioration * 1/197 (0.51%)",
        "  Contrast media reaction * 1/197 (0.51%)",
        "  Cachexia * 1/197 (0.51%)",
        "  Bone pain * 1/197 (0.51%)",
        "  Metastases to central nervous system * 1/197 (0.51%)"
    ]
}